AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cardiff Oncology Inc. (CRDF)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.70

-0.08 (-1.67%)

At close: Feb 20, 2025, 3:59 PM

4.79

2.02%

After-hours: Feb 20, 2025, 06:43 PM EST

undefined% (undefined)

Bid	4.75
Market Cap	312.30M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.95
PE Ratio (ttm)	-4.94
Forward PE	n/a
Analyst	Buy

Ask	4.79
Volume	1,310,729
Avg. Volume (20D)	2,129,044
Open	4.82
Previous Close	4.78
Day's Range	4.38 - 4.86
52-Week Range	1.65 - 6.42
Beta	undefined

About CRDF

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevac...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 27, 2004

Employees 31

Stock Exchange NASDAQ

Ticker Symbol CRDF

Website https://www.cardiffoncology.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 112.99% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Cardiff Oncology Inc. is scheduled to release its earnings on Mar 3, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+19.88%

Cardiff Oncology shares are trading higher after P... Unlock content with Pro Subscription

2 months ago

+54.92%

Cardiff Oncology shares are trading higher after the company announced the initial data from its CRDF-004 Phase 2 trial evaluating Onvansertib.

News

3 days ago · seekingalpha.com

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II resu...

2 months ago · seekingalpha.com

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational im...

2 months ago · seekingalpha.com

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when...

2 months ago · zacks.com

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.

2 months ago · seekingalpha.com

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Cardiff Oncology's Phase 2 trial data for Onvansertib in metastatic colorectal cancer shows dose-related outperformance of standard care, with a combined ORR of 57% versus 33% in the control arm. The ...